Girard Sharp LLP is investigating potential claims on behalf of Illumina stockholders.
If you were a GRAIL stockholder and received Illumina stock, please fill out our form or call (866) 981-4800 for a free consultation.
Illumina (NASDAQ: ILMN) Stock Declines %30
In September 2020, Illumina, a genetic testing company, reacquired its subsidiary GRAIL. In August 2023, Illumina announced that the SEC was investigating its acquisition of GRAIL and, in October, shareholders filed a class action lawsuit against Illumina, alleging a breach of fiduciary duty. Over this period, Illumina’s share price declined by roughly 30%.
If you are an Illumina stockholder, fill out our contact form to speak to a Girard Sharp securities attorney about your rights.
Our Commitment to Excellence
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We serve on the Plaintiffs’ executive committee in the recent spoofing litigation against JPMorgan Chase that settled for $60 million, a favorable resolution that the district court preliminarily approved in December 2021. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
